SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification

被引：3
|
作者：
Yu, Y. [1 ]
Yang, N. [2 ]
Zhang, Y. [3 ]
Zhang, H. [4 ]
Li, M. [5 ,16 ]
Yu, Q. [6 ]
Zhou, J. [7 ]
Hu, X. [8 ]
Fang, J. [9 ]
Zhao, H. [10 ]
Feng, J. [11 ]
Li, L. [12 ]
Shu, Y. [13 ]
Wang, X. [14 ]
Sun, M. [15 ]
Zhang, J. [15 ]
Li, M. [5 ,16 ]
Ren, Y. [15 ]
Lu, S. [1 ]
机构：
[1] Shanghai Chest Hosp, Dept Oncol, Shanghai, Peoples R China
[2] Hunan Canc Hosp, Pulm Gastroenterol, Changsha, Peoples R China
[3] Zhejiang Canc Hosp, Med Oncol, Hangzhou, Peoples R China
[4] Guangdong Prov Hosp Chinese Med, Dept Internal Med 1, Guangzhou, Peoples R China
[5] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[6] Guangxi Med Univ, Affiliated Tumor Hosp, Resp Oncol Dept, Nanning, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 1, Resp Med Dept, Hangzhou, Peoples R China
[8] Henan Tumor Hosp, Med Oncol, Zhengzhou, Peoples R China
[9] Beijing Canc Hosp, Dept Thorac Oncol, Beijing, Peoples R China
[10] Anhui Med Univ, Hosp 2, Dept Pneumol, Hefei, Peoples R China
[11] Nantong Univ, Affiliated Hosp, Dept Resp & Crit Care Med, Nantong, Peoples R China
[12] Sichuan Univ, West China Hosp, Resp Dept, Lung Canc Ctr, Chengdu, Peoples R China
[13] Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[14] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan, Peoples R China
[15] Haihe Biopharma Co Ltd, CSSD, Shanghai, Peoples R China
[16] Haihe Biopharma Co Ltd, BDS, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.10.334
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305MO
引用
下载
收藏
页码：S1553 / S1553
页数：1
相关论文
共 50 条
  • [41] Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
    Liam, Chong Kin
    Ahmad, Azura Rozila
    Hsia, Te-Chun
    Zhou, Jianying
    Kim, Dong-Wan
    Soo, Ross Andrew
    Cheng, Ying
    Lu, Shun
    Shin, Sang Won
    Yang, James Chih-Hsin
    Zhang, Yiping
    Zhao, Jun
    Berghoff, Karin
    Bruns, Rolf
    Johne, Andreas
    Wu, Yi-Long
    CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1879 - 1886
  • [42] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
    Xu, Q.
    Liu, H.
    Hang, T.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
  • [43] A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations
    Lu, S.
    Zhou, J.
    Niu, X.
    Chen, M.
    Hua, Y.
    Su, W.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1735 - S1735
  • [44] The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study
    Yin, Xiaoyan
    Liu, Xinchao
    Ren, Fei
    Meng, Xiangjiao
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (07)
  • [45] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
  • [46] A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
    Yang, J. -
    Fang, J.
    Shu, Y.
    Chang, J.
    Chen, G.
    He, J.
    Li, W.
    Liu, X.
    Yang, N.
    Zhou, C.
    Huang, J.
    Yang, L.
    Handzel, A.
    Frigault, M.
    Ahmed, G.
    Egile, C.
    Morgan, S.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1769 - S1769
  • [47] The first- or second-line use of pemetrexed sequentially with EGFR-TKI did not differ in PFS for advanced NSCLC patients harboring EGFR-mutant tumors.
    Ding, Zhen-Yu
    Chen, Yue-Yun
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
    Sequist, Lecia V.
    Lee, Jong Seok
    Han, Ji-Youn
    Su, Wu-Chou
    Yang, James Chih-Hsin
    Yu, Helena
    Ottesen, Lone H.
    Verheijen, Remy B.
    Mellemgaard, Anders
    Wessen, Jonathan
    Oxnard, Geoffrey
    Cho, Byoung Chul
    CANCER RESEARCH, 2019, 79 (13)
  • [49] SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET driven (MET plus ), locally advanced or metastatic non small cell lung cancer (NSCLC), following disease progression on osimertinib.
    Oxnard, Geoffrey R.
    Cantarini, Mireille
    Frewer, Paul
    Hawkins, George
    Peters, Jane
    Howarth, Paul
    Ahmed, Ghada F.
    Sahota, Tarjinder
    Hartmaier, Ryan
    Li-Sucholeiki, Xiaocheng
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib
    Yu, Helena Alexandra
    Kerr, Keith
    Rolfo, Christian Diego
    Fang, Jian
    Finocchiaro, Giovanna
    Wong, Kam-Hung
    Veillon, Remi
    Kato, Terufumi
    Yang, James Chih-Hsin
    Nadal, Ernest
    Raskin, Jo
    Le, Xiuning
    Karachaliou, Niki
    Ellers-Lenz, Barbara
    OBrate, Aurora
    Stroh, Christopher
    Piske, Nadine
    Boesler, Carsten
    Yang, Jinji
    Mazieres, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345